Clear-cell renal cell carcinoma is a highly treatment-resistant tumor type. Heme oxygenase-1 plays an anti-apoptotic role in cancer chemotherapeutic inducing tumor-progression. The miR-200 family was involved in the process of mesenchymal-epithelial transition (MET) during renal development. In the present study, we demonstrated the regulatory relationship between miR-200c and HO-1. We provided evidences to elucidate that miR-200c could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation, at least partly by targeting HO-1. Moreover, the correlation between miR-200c and HO-1 expression level and drug resistance in ccRCC was also determined. Combined application with chemotherapeutic drugs, miR-200c, a HO-1 inhibitor, may enhance the efficiency of therapy by promoting both apoptosis and autophagy.
Renal cell carcinoma (RCC), one of the leading lethal causes of cancers, affects about 120,000 deaths worldwide annually with steadily rising. The large part (~75%) of cases is clear-cell RCC (ccRCC), which is a highly treatment-resistant tumor type. Emerging investigates are elucidating the molecular mechanisms underlying RCC and promising targets for therapeutics. In clear-cell RCC, mutations of genes result in the up-regulation or down-regulation of many proteins necessary for tumor growth, survival and angiogenesis, such as vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) [1] . Sorafinib (Nexavar, BAY 43-9006), one of the potent inhibitors of the class of Raf kinase, has been applied in clinical. Sorafinib is an orally available, novel bi-aryl urea compound that represses tumor growth and metastases by targeting the receptor tyrosine kinases VEGFR and PDGFR to inhibit angiogenesis and proliferation [2] . Imatinib (Gleevec), an inhibitor of bcr-abl, PDGF receptor (PDGFR) and the c-kit tyrosine kinases, has been approved by the Food and Drug Administration (FDA) for the treatment of gastrointestinal stromal tumors [3] .
Heme oxygenase-1 (HO1), the rate-limiting enzyme in heme degradation with a strong anti-inflammatory and antiapoptotic role, can protect against various injuries, such as ischemic-reperfusion injury [4] . However, the advantages in anti-apoptotic and cytoprotective roles of HO-1 turn out to induce tumor-progression in cancer chemotherapeutic [5] . It was reported that increased expression of HO-1 in human malignant cancer tissue was observed, such as lung cancers [6] . One of reports showed that high expression of HO-1 was associated with poor prognosis in lung cancer [7] . On the contrary, other studies reported that high HO-1 expression was also associated with favorable prognosis in colorectal cancer patients. Moreover, it was recently reported that HO-1 nuclear localization was involved in imatinib resistance in chronic myeloid leukemia cells [8] , indicating the increased significance of HO-1 in cancer biology. Despite of these conflicting results, it is necessary to determine the role of HO-1 in human malignant tumors.
MicroRNAs(miRNAs), about 22 nt long noncoding regulatory RNAs, show promise as diagnostic biomarkers and therapeutic targets for cancer [9] . Aberrant expression of miRNAs, as oncogenes or tumor suppressors, plays an important role in the pathogenesis, invasion and metastasis of various malignant tumors. Deregulation of several miRNAs has been found in nephroblastomas. Most of the downregulated miRNAs were found silenced through epigenetic mechanisms in solid cancers including breast cancer [10] and neuroblastoma [11] . The tissues of ovarian tumors and nephroblastomas showed a significantly decreased expression of miR-185 [12] . The miR-200 family was involved in the process of mesenchymal-epithelial transition (MET) during renal development [13] . A recent study found that miR-200c was dramatically decreased in clear cell renal carcinomas compared with non-malignant samples [14] . It was showed that restoration of mature miR-200c in renal cell carcinoma markedly inhibited cancer cell proliferation, suggesting that miR-200c might be a candidate tumor suppressor. However, the precise mechanisms underlying regulation of miR-200c in ccRCC remain unclear.
In this study, we aim to investigate the relationship between HO-1 and miR-200c in chemotherapeutic resistance in ccRCC, and explore their functions involved with apoptosis and autophagy. In the present study, we demonstrated the regulatory relationship between miR-200c and HO-1. We provided evidences to elucidate that miR-200c, at least partly by targeting HO-1, could sensitize ccRCC cells to sorafenib or imatinib to inhibit cell proliferation via apoptosis and autophagy pathway.
Materials and methods
Cells culture and treatment. HEK293, SN12C, ACHN, 786-O and Caki-1 cells, were obtained from American type culture collection (ATCC) and cultivated in RPMI-1640 medium with fetal bovine serum to a final concentration of 10%. All cells cultured in the conditions: 95% air and 5% carbon dioxide (CO2) at 37°C.
Sorafenib-or imatinib-resistant 786-O and Caki-1 cells were treated with gradually increasing concentrations of sorafenib (1μM to 20μM) or imatinib (1mmol/L to 20mmol/L) in cell culture medium. These cells were used as resistant RCC cell lines for subsequent experiments. Ectopic expression of miR-200c in cells was achieved by transfection with pre-miR-200c or anti-miR-200c using Lipofectamine2000 (Invitrogen, USA). Knockdown of HO-1 was performed using HO-1 siRNA (Qiagen). Cells were plated in 24-well plates and transfected for 24 hours or 48 hours. Total RNA or protein was extracted from the indicated cells for analysis.
Reagents. Rabbit polyclonal antibody of HO-1 was purchased from Assay Biotech (Assay Biotech, USA). Mouse polyclonal antibodies of Beclin-1, LC3B, Bcl-xl, Bcl-2, Bid, Bax, and mouse monoclonal antibody of β-actin were purchased from ImmunoWay (ImmunoWay, USA). Sorafenib and imatinib were obtained from Sigma (Sigma, USA).
Quantitative PCR (qPCR) assay. Qiagen RNeasy Kit was used to extract total RNA of the indicated cells, according to the manufacturer's instructions. Expression of HO-1 mRNA was detected by SYBR green qPCR assay (BioRad, USA). Expression of β-actin was used as an endogenous control. The specific primers are as follow: HO-1, F: AGGCAGAG-GGTGATAGAAGAGGC, R: TGAGTGTAAGGACCCA TCGGAGA; β-actin, F: AGGGGCCGGACTCGTCATACT, R: GGCGGCACCACCATGTAC CCT. MiScript Reverse Transcription kit was used to reverse transcribe RNA into cDNA and MiScript SYBR-Green PCR Kit was used for real time PCR to detect the expression of miRNAs. The specific primers sets for miRNAs and U6 were purchased from GeneCopoeia. Expression of U6 was used as an endogenous control. Data were analyzed through 2 -ΔΔCT method. Methylation specific PCR (MSP). Genomic DNA was extracted using the TaKaRa Genomic DNA Extraction Kit (TaKaRa Co., China). Genomic DNA (1 μg per sample) was modified with bisulfite using the Epitect Bisulfite Kit Protocol (Qiagen) followed the manufacturer's instructions. Western blotting. Total protein (60 μg) extracted from indicated cells was separated on SDS-polyacrylamide gels for HO-1, Beclin-1, Bcl-xl, Bim, Bax and β-actin detection. β-actin was used as loading control. The protein in gels was transferred to nitrocellulose membranes, and then incubated with the indicated antibodies in recommended dilution for overnight at 4°C. Then membranes were washed with 0.1M PBST and incubated with HRP-conjugated secondary antibody. Signals were visualized using ECL Substrates and quantified using Optiquant software.
CCK-8 cell proliferation assay. Cell Counting Kit-8 (CCK-8) (Solarbio, China) was used to evaluate cell proliferation rates. 0.5 ×10 4 cells were seeded in each 96-well plate for 24 h, transfected with the indicated miRNA or siRNA, and further incubated for 0h, 24 h, and 48 h respectively. 1h before ending of incubation, 10 μl CCK-8 reagents was added to each well. OD 450nm value in each well was determined by an enzyme immunoassay analyzer.
Dual luciferase reporter assay. The indicated cells were seeded in 96-well plates the day before transfection. Then, cells were cotransfected with 25 ng pmiR-report 3'UTR HO-1 target gene and 10 ng pRL-TK (Renilla plasmid), and 15 nM pre-miR-200c or anti-miR-200c using Lipofectamine 2000. Cells were transfected for 48 hours with Dual-LuciferaseReporter Assay System and luminescence was detected using a luminometer (Promega). The luciferase activity was normalized to the Renilla activity.
Statistical analysis. Data are expressed as mean ± SD and analyzed by Student's t-test. Compared with respective controls, P values of <0.05 were considered statistically significant. To identify whether the 3'-untranscriptional region (3'-UTR) of HO-1 had a direct target site for miR-200c or not, a dual luciferase reporter assay was performed using a vector encoding the wild type (Wt) and mutant (Mut) 3'UTR of HO-1 mRNA (Figure 2A) , and it was found that the luminescence activity was significantly repressed in the miR-200C transfectants compared to the control-transfectant ( Figure  2B ). Moreover, miR-200c-mediated repression of luciferase activity was abolished by the mutant type 3'UTR of HO-1 ( Figure 2B ). These results determine that miR-200c directly targets HO-1 and regulates its expression at transcriptional level. (Figure 2D 
Discussion
Downregulation of miR-200c was observed in the whole RCC succession. It was reported that miR-200c could suppress epithelial-to-mesenchymal transition (EMT)-driven resistance, regulate the sensitivity of chemotherapy in gastric cancer [15] , and contribute to antiestrogen resistance in human breast cancer [16] . Based on these findings, we speculated miR200c might be also involved in ccRCC treatment-resistant. In our recent research, we confirmed the relationship between miR-200c and HO-1, and found that miR-200c inhibited ccRCC cell proliferation by targeting HO-1.
By quantitative PCR, we validated that miR-200c was dramatically downregulated in ccRCC cell lines treatmentresistant to sorafenib or imatinib, which were consistent with previous studies on other cancers. Epigenetic modifications were prevalent in many cancers, and many research groups have reported comparisons of alterations in methylated micro-RNA expression for cancers [17] . MiRNAs themselves were able to be regulated by epigenetic mechanisms [18] . Here, we found that the promoter region of miR-200c was hypermethylated in renal carcinoma cell lines treated with sorafenib or imatinib than control, suggesting epigenetic mechanisms might be also involved in ccRCC treatment-resistant. We Heme oxygenase-1 (HO1), an anti-apoptotic gene, was involved in imatinib resistance in cancers [19] and the regulation of autophagy [20] . Mechanically, HO-1 transcriptionally involved in Beclin-1 and Bcl-2 signaling pathway, which has been reported essential for tumor growth and autophagy [21] . The two parts of pro-(Bax, Bak, Bad) and anti-apoptotic (Bcl-2, Bcl-xL) members comprised Bcl2 family, which played as a key regulator of apoptosis [22] and a crucial factor in tumor development. Thus, upregulation of anti-apoptotic members, or downregulation of the pro-apoptotic members of the Bcl-2 family would result in tumor progression. It has been found that increased expression of Bcl-xL was involved in resistance to chemotherapeutic drugs [23] . In our recent study, we found that decreased expression of HO-1 induced by pre-miR-200c or siRNA-HO-1 transfection markedly reduced Bcl-xL, and increased Bid and Bax in renal cancer cells, with slight change but not significant in expression of Bcl-2. Although both Bcl-xL and Bcl-2 are known to enhance antiapoptotic signals, it is considered that Bcl-xL was involved in chemoresistance. According previous studies and our recent results, it is possible that promotion of apoptosis by modulation of Bcl-xL, Bid and Bax is one of the possible mechanisms underlying miR-200c-mediated cancer cell death by targeting HO-1. Furthermore, recent studies indicate that cancer cell death is also controlled by autophagy interplay with apoptosis. During late or advanced stages of cancer, by supplementing the growing needs of the cells with excess supply of oxygen and nutrients, autophagy comes as a savior in cancer [24] . Moreover, some reports showed that autophagy promoted apoptotic functions of chemotherapeutic drugs, but others indicated that it may act as a survival factor of cancer cells in drugs treatment [25] . Our recent results showed that upregulation of miR-200c or downregulation of HO-1 decreased some key mediators (Beclin-1 and LC3B) of the autophagy pathway. Beclin-1, one of the most critical molecules in the autophagy pathway, is an integral part of PI3K multiprotein complex, which was essential for autophagosome nucleation. The interaction between Beclin-1 and anti-apoptotic members of Bcl-2 family has been demonstrated. Zalckvar and his colleagues reported that the dissociation of Beclin-1 from anti-apoptotic members of Bcl-2 family promotes autophagy [26] . Our findings indicated that miR-200c inhibited the association of Beclin-1 with its inhibitor Bcl-xL promoted by HO-1, and thereby may reduce autophagy. Of note, instead of protecting cells from apoptosis, autophagy can mediate cell death under specific circumstances [27] . It was reported that chemotherapeutic drugs promoted autophagy to kill tumor cells [28] , suggesting that cells may not only die by apoptosis, but also autophagy. We demonstrate that inhibition of both apoptosis and autophagy play a key role in miR-200c-mediated death of renal cancer cells.
In conclusion, this study found newly an important mechanism underlying miR-200c-mediated chemotherapeutic resistance of renal cancer cells. MiR-200c promoted cells to death by targeting to HO-1 to suppress both apoptosis and autophagy induced by sorafenib or imatinib. Thus, our work highlighted the significance of miR-200c as a potential therapeutic target for clear-cell renal cell carcinoma. Combined application with chemotherapeutic drugs, overexpression of miR-200c may enhance the efficiency of therapy.
